MEDICATIONS PRESCRIPTION AT HOSPITAL DISCHARGE IN PATIENTS WITH VALIDATED DIAGNOSIS OF DEMENTIA. Federica Edith Pisa University Hospital Udine

Similar documents
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia

American Medical Association, American Academy of Neurology Institute and American Psychiatric Association (2016)

Zhao Y Y et al. Ann Intern Med 2012;156:

Medical code list: possible Alzheimer's disease Read Code Read Term E Senile and presenile organic psychotic conditions E00..

Coding clean-up Exercise Guidance to GPs to improve dementia coding, and raise diagnosis rates. A step by step approach

Antipsychotic Medications

Supplementary Online Content

Dementia Benchmarking Indicators Definitions and Data Sources Manual

Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Changing patterns of sedative use over time in older adults in Ontario

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

National Audit of Dementia Round 4 (2018) Sampling guidance for the Casenote Audit

The validity of national hospital discharge register data on dementia: a comparative analysis using clinical data from a university medical centre

JAMA, January 11, 2012 Vol 307, No. 2

Local Improvement Scheme (LIS) 2016/17 Local Service for Dementia Care in East Lancashire GP Practices

Proposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)

An Increased Risk of Reversible Dementia May Occur After Zolpidem Derivative Use in the Elderly Population

RUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1

The South Carolina Alzheimer's Disease Registry: A Unique Asset for Statewide Surveillance and Research

Finland and Sweden and UK GP-HOSP datasets

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit

Silvia Duong, 1,2 Kam-Tong Yeung, 1 and Feng Chang 1,3. 1. Introduction

Response to Concerns of NQF Neurology Steering Committee

PHARMO Database Network

On-line Table 1: Dementia diagnoses and related ICD codes for the diagnostic groups a

Nuplazid. Nuplazid (pimavanserin) Description

Following the health of half a million participants

COGNOS. Care for people with Cognitive dysfunction A National Observational Study. Professor Dr Jan De Lepeleire COGNOS members

Policy Evaluation: Low Dose Quetiapine Safety Edit

Rexulti (brexpiprazole)

Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer s disease in Finland

The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias

Delirium in the Elderly

Community Pharmacy Dementia Audit

Appendix D: Included Studies adverse effects review

Karen Tu MD, MSc, CCFP, FCFP Scientist ICES Associate Professor DFCM, University of Toronto Active Staff Toronto Western Hospital FHT

Antipsychotic Prior Authorization Request

Schizophrenia, a devastating chronic. Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program

METHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

Delirium in the Elderly

Potentially Inappropriate Medications in Elderly Patients: Prevalence at Admission and Changes During Hospital Stay

Evaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:

Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia A Nationwide Study With 20-Year Follow-up

Cardiovascular Health and Diabetes Screening for People with Schizophrenia

Challenges in design and analysis of large register-based epidemiological studies

Updates and Clarifications to the Hospice Policy Chapter of the Benefit Policy Manual. Compliance for Hospice Providers Revised September 2014

Antipsychotics and stroke risk

Adverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease

Cognitive disorders. Dr S. Mashaphu Department of Psychiatry

CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES?

Drug Use Evaluation: Low Dose Quetiapine

Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form

DEMENTIA AND MEDICATION

Canadian Practices for the Treatment of Delirium. Lisa Burry, BScPharm, PharmD

Do Elderly Men Have Increased Mortality Following Hip Fracture?

Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years

Legemiddelbruk og hoftebrudd

Research Protocol for REAP Bipolar Disorder (REAP-BD)

UNHEALTHY ALCOHOL USE SCREENING and FOLLOW-UP (ASF) HEDIS (Administrative)

Supplementary Online Content

Summary of funded Dementia Research Projects

High Dose Antipsychotic Therapy (HDAT) guideline

DIABETES ASSOCIATED WITH ANTIPSYCHOTIC USE IN VETERANS WITH SCHIZOPHRENIA

The Correlation of Patients with Spinal Cord Injury and Psychiatric Disorders. Ching Hui, Chuang Chung Hey, Chen

Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A

Assessing and Managing the Patient with Cognitive Decline

Dementia Care in Acute Hospitals. A Report from the Dementia Action Alliance. South East Coast Region

Supplementary Online Content

Opioid use in COPD: balancing benefits and harms. St. Michael s Hospital, University of Toronto

Ann Rheum Dis 2017;76: doi: /annrheumdis Lin, Wan-Ting 2018/05/161

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Westminster Memory Services Pathways Toolkit (updated October 2016)

4/26/2012. Laura Grooms, MD Assistant Professor Geriatric Medicine Department of Family and Geriatric Medicine University of Louisville April 20, 2012

Looking for Balance: Antipsychotic medication use in Ontario long-term care homes. Technical Appendix

Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents

Health Issues for Aging Populations

Appendix K: Evidence review flow charts

Risk of Upper Gastrointestinal Complications in Users of Nonsteroidal Anti-inflammatory Drugs

Integrating INTERACT into Interim Pharmacist Reviews

Table 2. Distribution of Normalized Inverse Probability of Treatment Weights. Healthcare costs (US $2012) Notes:

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.

Drug Surveillance and Effectiveness Epidemiology Research - Questions to Ask your Epidemiologist

Research on medication in the geriatric health services facility Abstracts

MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE

University of Groningen. Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia

Management of Agitation in Dementia. Kimberly Triplett Ferguson, MS4

Young onset dementia service Doncaster

Psychosis and Agitation in Dementia

SUPPLEMENTAL MATERIALS FOR:

The Wennberg International Collaborative, London, 2-4 September 2015

Molina Healthcare of Texas

The chronic nature of schizophrenia is a major contributor

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source

Transcription:

MEDICATIONS PRESCRIPTION AT HOSPITAL DISCHARGE IN PATIENTS WITH VALIDATED DIAGNOSIS OF DEMENTIA Federica Edith Pisa University Hospital Udine

BACKGROUND Polypharmacy and psychotropic medication use are very common in elderly patients with dementia [Bohlken J et al, 2015; Barry H et al, 2016; Walsh KA et al, 2016; Schmed N et al, 2016] 64.4% prevalence of potentially inappropriate prescribing [Barry H et al, 2016] Antipsychotics off-label for neuropsychiatric symptoms are discouraged by international guidelines Increased risk of severe adverse events and death [Ray WA et al, 2009; Wang PS et al 2005; Trifiro G et al, 2010 ]

Drug utilization studies based on registry [Johnell K et al, 2013] or claims data [Bohlken J et al, 2015; Barry H et al, 2016] Focus on community-dwelling patients, on the long-term care or primary care setting [Sultana J et al, 2016; Barry H et al, 2016] In hospitalized elderly, dementia associated with a 2-fold increased risk of antipsychotic initiation [Herzig SJ et al, 2016] and with high prevalence of psychotropic polypharmacy [Walsh KA et al, 2016]

Many validation studies of codes/algorithms for identifying health outcomes in health databases in Europe [Schmidt M et al, 2015; Ludvigsson J et al, 2011; Jick S et al, 2002] Dementia: o based on medical chart review [van de Vorst et al, 2015; Phung et al, 2007; Pippenger et al, 2001 USA] o based on clinical diagnosis in cohort studies [Jin et al, 2004; Solomon, 2014]

OBJECTIVES To validate discharge codes used to identify cases of dementia in an hospitalization database In patients with a confirmed diagnosis of dementia, to describe the pattern of medication: o used at hospital admission o prescribed at discharge o dispensed after discharge

This study was conducted at the University Hospital of Udine, Friuli Venezia Giulia region (FVG), Italy FVG Regional Health Services Databases with anonymized individuallevel linkable information on the use of health care resources FVG regional Ethics Committee approval FVG Region (1.2 million population)

Data sources FVG Health Databases ohospital Services METHODS ooutpatient Prescriptions (dispensing) opatient Identification (demographic and vital information) Electronic Medical Records EMR o clinical data on in- and out-patient medical care encounters

Study population any hospitalization from 1 January 2012 to 31 December 2014 at the University Hospital of Udine with primary or secondary ICD-9-CM discharge code for dementia dementia ICD-9-CM code senile 290.0, 290.2, 290.3 presenile 290.1 vascular 290.4 degenerative 290.9 alcohol persistent 291.2 drug persistent 292.82 in other diseases/ unspecified 294.1, 294.2, 294.8 frontotemporal 331.1, 331.19 Lewy body 331.82 Jakob-Creutzfeldt disease 046.1 Alzheimer s disease 331.0 general paresis 094.1 Pick s disease 331.11

Validation EMR review Gold standard: diagnosis of dementia and/or moderate-severe cognitive impairment written by treating physician or neurologist/psychiatrist Not confirmed cases: mild cognitive impairment, other diagnosis, wrong code Review and abstraction by two trained MDs Final case confirmation independently by two research epidemiologists

Data abstraction From EMR opatient demographic characteristics odischarge diagnosis written by treating physician odiagnosis written by consultant neurologist/psychiatrist oneurological / psychiatric comorbidities oother comorbidities odate of onset of dementia (when available) odischarging division omedications registered at admission (agent, formulation, dose) omedications prescribed at discharge (agent, formulation, dose)

Data abstraction From Health Databases o all prescriptions from January 1st, 2002 to December 31, 2015 o residential history (emigration from FVG) o date and cause of death up to December 31, 2015 (end of study period)

Study design Retrospective cohort study Any patient with confirmed diagnosis of dementia Follow-up for prescriptions dispensed o from date of discharge of the 1st hospitalization with confirmed diagnosis (index hospitalization) o to the earliest of the following dates: death emigration / disenrollment from regional health system 1 year after index hospitalization December 31, 2015 (end of study period)

Statistical analysis Positive Predictive Value (PPV), with 95% confidence interval (95%CI), as the ratio of hospitalizations with confirmed diagnosis to those with potential diagnosis number and distribution of selected medications prescribed at discharge in patients with confirmed dementia SAS software, version 9.3 (SAS, Cary, NC, USA)

RESULTS Table 1. Positive Predictive Value (PPV) for dementia, with 95% Confidence Interval (95%CI), ICD-9-CM primary and secondary diagnosis code. N of records Type of confirmation (written diagnosis) codes for dementia with EMR confirmed diagnosis N (%) N (%) N EMR retrieval % PPV 95%CI by discharging physician dementia 1168 0.40 0.38-0.41 cognitive impairment 1 1200 0.41 0.39-0.42 3104 (100.0) 2951 (100.0) 95.1 dementia / cognitive impairment 2368 0.80 0.79-0.82 by discharging physician / neurologist dementia / cognitive impairment 2500 0.85 0.83-0.86 code position primary 505 (16.3) 480 (16.3) 390 95.0 0.81 0.78-0.85 1 moderate-severe. any secondary 2599 (83.7) 2471 (83.7) 2110 95.1 0.85 0.84-0.87

Table 2. Positive Predictive Value (PPV) for dementia, with 95% Confidence Interval (95%CI), ICD-9-CM primary and secondary diagnosis code. By patient demographic characteristics and discharging division. age (years) sex with EMR (N= 2951) N of records confirmed diagnosis (N= 2500) PPV 95%CI N (%) N (%) <85 1341 (45.4) 1106 (44.2) 0.82 0.80-0.84 85 + 1610 (54.6) 1394 (55.8) 0.87 0.85-0.88 Women 1885 (63.9) 1612 (64.5) 0.86 0.84-0.87 Men 1066 (36.1) 888 (35.5) 0.83 0.81-0.85 discharging division neurology 271 (9.2) 209 (8.4) 0.77 0.72-0.82 surgery 216 (7.3) 186 (7.4) 0.86 0.81-0.91 medicine 2464 (83.5) 2105 (84.2) 0.85 0.84-0.87

Table 3. Positive Predictive Value (PPV), with 95% Confidence Interval (95%CI), ICD-9-CM primary and secondary diagnosis code. By type of dementia. type of dementia (ICD-9-CM code) senile (290.0; 290.2; 290.3) codes for dementia (N= 3104) N of records with EMR (N= 2591) confirmed diagnosis (N= 2500) N (%) N (%) N (%) EMR retrieval % PPV 95%CI overall 1436 (46.3) 1342 (51.8) 1161 (46.4) 93.5 0.87 0.85-0.88 primary position 169 (5.4) 158 (6.1) 126 (5.0) 93.5 0.80 0.73-0.86 secondary position 1267 (40.8) 1184 (45.7) 1035 (41.4) 93.4 0.87 0.85-0.89 vascular (290.4) overall 1205 (38.8) 1170 (45.2) 953 (38.1) 97.1 0.81 0.79-0.84 primary position 170 (5.5) 166 (6.4) 142 (5.7) 97.6 0.86 0.80-0.91 secondary position 1035 (33.3) 1004 (38.7) 811 (32.4) 97.0 0.81 0.78-0.83 presenile (290.1) overall 172 (5.5) 169 (6.5) 135 (5.4) 98.3 0.80 0.74-0.86 primary position 73 (2.3) 72 (2.8) 45 (1.8) 98.6 0.63 0.51-0.74 secondary position 99 (3.2) 97 (3.7) 90 (3.6) 98.0 0.93 0.88-0.98 Alzheimer s disease (331.0) overall 187 (6.0) 170 (6.6) 168 (6.7) 90.9 0.99 0.97-1.00 primary position 23 (0.7) 21 (0.8) 21 (0.8) 91.3 1.00 1.00-1.00 secondary position 164 (5.3) 149 (5.7) 147 (5.9) 90.9 0.99 0.97-1.00

561 patients had 1 hospitalization 1939 patients had confirmed diagnosis of dementia 254 (13.1%) patients died during in-hospital stay

Table 4. Number and distribution of patients with validated diagnosis of dementia by selected covariates. (N= 1685) N (%) age (years) <65 56 (3.3) 65-74 171 (10.1) 75-84 569 (33.8) 85+ 889 (52.8) sex female 1085 (64.4) male 600 (35.6) type of dementia (ICD-9-CM code) presenile (290.1) 105 (6.2) senile (290.0; 290.2; 290.3) 761 (45.2) vascular (290.4) 625 (37.1) Alzheimer s disease (331.0) 103 (6.1) other 1 91 (5.4) psychiatric comorbidity depression 204 (12.1) psychosis 35 (2.1) other 142 (8.4) total 381 (22.6) medications at discharge (N) 1 to 3 381 (22.6) 4 to 6 651 (38.6) 7 or more 653 (38.7) discharging division neurology 180 (10.7) surgery 165 (9.8) medicine 1340 (79.5) 1 Includes: alcohol persistent dementia (291.2), drug persistent dementia (292.82), dementia in other diseases/ unspecified (294.1, 294.2, 294.8), frontotemporal dementia (331.1, 331.19), Lewy body dementia (331.82), Jakob-Creutzfeldt disease (046.1), general paresis (094.1), degenerative dementia (290.9), Pick s disease (331.11).

Table 5. Psychotropic medication prescribed at discharge in patients with validated diagnosis of dementia. Antipsychotics (N05A) (N= 684; 40.6%) Antidepressants (N06A) (N= 337; 20.0%) Anti-dementia agents (N06D) (N= 242; 14.4%) Anxiolytics (N05B) (N= 136; 8.1%) Hypnotics and sedatives (N05C) (N= 70; 4.1%) age (years) N (%) N (%) N (%) N (%) N (%) <65 16 (2.3) 11 (3.3) 15 (6.2) 6 (4.4) 2 (2.9) 65-74 70 (10.2) 55 (16.3) 55 (22.7) 22 (16.2) 7 (10.0) 75-84 234 (34.2) 138 (40.9) 108 (44.6) 56 (41.2) 30 (42.9) 85+ 364 (53.2) 133 (39.5) 64 (26.4) 52 (38.2) 31 (44.3) sex female 427 (62.4) 235 (69.7) 140 (57.9) 97 (71.3) 47 (67.1) male 257 (37.6) 102 (30.3) 102 (42.1) 39 (28.7) 23 (32.9) type of dementia (ICD-9-CM code) presenile (290.1) 38 (5.6) 27 (8.0) 29 (12.0) 13 (9.6) 4 (5.7) senile (290.0; 290.2; 290.3) 312 (45.6) 149 (44.2) 110 (45.5) 59 (43.4) 37 (52.9) vascular (290.4) 240 (35.1) 114 (33.8) 49 (20.2) 52 (38.2) 22 (31.4) Alzheimer s disease (331.0) 48 (7.0) 26 (7.7) 41 (16.9) 7 (5.1) 4 (5.7) other 1 46 (6.7) 21 (6.2) 13 (5.4) 5 (3.7) 3 (4.3) prior psychiatric morbidity depression 87 (12.7) 102 (30.3) 58 (24.0) 17 (12.5) 13 (18.6) psychosis 22 (3.2) 11 (3.3) 3 (1.2) 6 (4.4) 1 (1.4) other 58 (8.5) 50 (14.8) 22 (9.1) 26 (19.1) 16 (22.9) total 167 (24.4) 163 (48.4) 83 (34.3) 49 (36.0) 30 (42.9) discharging division neurology 62 (9.1) 67 (19.9) 66 (27.3) 12 (8.8) 12 (17.1) surgery 85 (12.4) 41 (12.2) 39 (16.1) 17 (12.5) 11 (15.7) medicine 537 (78.5) 229 (68.0) 137 (56.6) 107 (78.7) 47 (67.1)

STRENGHTS AND LIMITATIONS Strengths EMR retrieval almost complete Linkage with outpatient prescriptions dispensing data Limitations 1 University Hospital No data on laboratory and imaging examinations No indication of prescriptions Medication at admission registered by nurses from available medical documentation or caregivers reports

CONCLUSIONS Pisa, 2016 (N= 2951) van de Vorst, 2015 (N= 340) 1 Phung, 2007 (N= 200) 1 Pippenger, 2001 (N= 240) 1 Dementia type PPV PPV PPV PPV Overall 85 93.2 96.9 76.9 Senile 87 - - 88.9 Presenile 80 - - 94.4 Vascular 81 91.3 96.3 - Alzheimer s disease 99 100.0 96.5 97.7 1 Random sample of records.

Validation of codes Setting- and study- specific factors: o local coding practices, coding purpose, attitudes and knowledge by local physicians o differences in study design (e.g. set of codes includes) o background prevalence PPV for Alzheimer s disease very high, consistently with prior research [van de Vorst, 2015; Phung, 2007; Pippenger, 2001] PPV higher in older patients, consistently with prior research [van de Vorst, 2015]

Prescriptions at discharge Anti-dementia agents o 14.4%, lower than in other studies [Bohlken J et al, 2015; Johnell K et al, 2013] o 39.8% (41/103) in Alzheimer s Disease, (a) consistently recommended by guidelines and (b) reimbursed in Italy Antidepressants o 69.7% women, consistently with previous research [Bohlken J et al, 2015]

Prescribing at discharge Antipsychotics o 40.6%, higher than in other studies [Bohlken J et al, 2015; Johnell K et al, 2013] o 30% prevalence in dementia in Italy in 2012 from GPs data [Sultana J et al, ICPE 2016]

COMMENTS The results will help us profiling true cases of dementia to develop identification algorithms Analysis of prescriptions dispensed after discharge o GPs confirm prescriptions at discharge and patients redeem prescribed medications o the use of antipsychotics is short-term as recommended

ACKNOWLEDGMENTS Prof. Giancarlo Logroscino, Neurodegenerative Disease Unit, Department of Neurosciences and Sense Organs, University of Bari, for insightful comments and suggestions. Dr. Francesca Palese and dr. Federico Romanese, collaborators

Thank you for your attention

BACK UP SLIDES

Validation strategies and case definition criteria in selected validation studies of hospital discharge codes for Dementia source for confirmation first author, year of publication gold standard coding system dementia type (codes) medical records review clinical diagnoses from cohort study van de Vorst, 2015 Phung, 2007 Pippenger, 2001 Solomon, 2014 Jin, 2004 diagnosis written by physician diagnosis written by physician diagnosis written by physician in-person cognitive tests + neuropsychological examinations screening interview + clinical evaluation ICD-9 senile (290.0, 290.3), presenile (290.1), vascular (290.4), Alzheimer D (331.0), frontotemporal (331.1), Lewy bodies (331.82), D classified elsewhere (294.1) ICD-10 Alzheimer D (F00.0, F00.1, F00.2, F00.9, G30.0, G30.1, G30.8, G30.9), vascular (F01.0, F01.1, F01.2, F01.3, F01.8, F01.9), frontotemporal (F02.0), without specification (F03.9) ICD-9 unspecified psychosis (298.9), presenile (290.1), vascular (290.4), senile (290.0, 290.2, 290.3), other organic brain syndrome (294.8), D classified elsewhere (294.1), Alzheimer D (331.0), encephalopathy (348.3), obstructive hydrocephalus (331.4), Pick s disease (331.1), other general symptoms (780.9) ICD-8 senile and presenile (290), presenile (290.10) ICD-9 dementia (290), alcohol persistent dementia (291.2), drug-induced mental disorders (292.8), dementia in other diseases (294.1), Alzheimer D (331.0), frontotemporal (331.1), other cerebrovascular disease (437.8) ICD-10 Alzheimer D (F00, G30), vascular (F01), classified elsewhere (F02), unspecified (F03), delirium superimposed (F05.1), alcohol persistent (F10.73), drug persistent (F11.73, F14.73, F16.73, F18.73, F19.73) ICD-8 Senile (290), presenile, Alzheimer D, Pick s disease, Jakob-Creutzfeldt disease with D (290.1), cerebral arteriosclerosis (293.0) ICD-9 dementia (290), due to secondary causes (294), Alzheimer D (331.0) ICD-10 Alzheimer D (F00.0, F00.1, F00.2, F00.9, G30.0, G30.1, G30.8, G30.9), Lewy bodies (G318), localized cerebral atrophy (G31.0), vascular (F01.0, F01.1, F01.2, F01.3, F01.8, F01.9), Pick s disease (F02.0), Creutzfeldt-Jakob disease (F02.1), Parkinson s disease (F02.3), classified elsewhere (F02.8), unspecified (F03.9), delirium superimposed (F05.1)

Author, year of publication Country N subjects results Solomon et al, 2014 Finland 1972-98: 1403 1998-2008: 846 1972-2008: 744 1972-98: PPV 57.1 (18.4-90.1); Se 7.3 (2.0-17.6); 1998-2008: PPV 17.7 (9.2-29.5); Se 84.6 (54.6-98.1); 1972-2008: PPV 13.7 (5.7-26.3); Se 87.5 (47.3-99.7) Jin et al, 2004 Sweden 1243 Se 43.3%; Sp 98.05%; PPV 88.53%; NPV 98.05%

Validation studies of hospital discharge codes for dementia based on medical charts review Dementia type 1 Random sample of records. Alzheimer s disease PPV sample Overall Senile Presenile Vascular Author (publication year) Country size 1 PPV PPV PPV PPV van de Vorst et al (2015) the Netherlands 340 93.2 - - 91.3 100 Phung et al (2007) Denmark 200 96.9 - - 96.3 96.5 Pippenger et al (2001) USA 240 76.9 88.9 94.4-97.7

Doblhammer G et al, 2015 Trends in dementia prevalence Claims data from a German public health insurance company Validation procedure in 3 incremental steps: 1. outpatient services: only diagnoses verified by physician inpatient services: only discharge and secondary diagnoses 2. only diagnoses with a second occurrence during the same period, e.g. diagnoses by different physicians (neurologist/psychiatrist and GP or other specialist) or concurrent diagnoses in the inpatient and outpatient services 3. insured with a dementia diagnosis followed over a moving validation period of 3 years, 2007 to 2009, only those with 2 dementia diagnoses were considered as valid cases

Chodosh J et al, 2004 Survey of physicians and review of medical records in HMO, California. Physicians (N= 365) correctly identified 81% of patients with dementia and 44% of patients with mild cognitive impairment Medical records documented cognitive impairment in 83% of patients with dementia and 26% of patients with cognitive impairment Geriatricians recognized cognitive impairment more often vs. non geriatricians Medical record documentation reflects physician recognition of dementia

Dahl A et al, 2007 N= 498 elderly cohort twin study (Gender), Sweden Follow-up 8 years Comparison of identification of dementia in cohort and medical records Review of medical records: sensitivity 57%, specificity 99%, kappa 0.65 Accuracy of medical records increased when recordings of cognitive impairment were included: sensitivity 83%, specificity 98%, kappa 0.84

Validation of codes PPV 77% discharges from neurology division: accurate diagnosis in clinical documentation, but not in coding PPV 81% primary codes: in-hospital delirium how accurate is the gold standard? o errors in reporting o dementia not diagnosed

Antipsychotics used at admission and prescribed at discharge. Patients with validated diagnosis of dementia. users at admission (N= 299) 1 prescribed at discharge (N= 684) antipsychotic agent N % 2 N % 3 atypical quetiapine 162 54.2 359 52.5 olanzapine 6 2.0 12 1.8 risperidone 6 2.0 10 1.5 clotiapine 2 0.7 7 1.0 clozapine 2 0.7 1 0.1 levosulpiride 12 4.0 23 3.4 tiapride 4 1.3 4 0.6 more than one atypical 4 1.3 12 1.8 subtotal atypical 190 63.4 404 59.1 typical promazine 85 28.4 203 29.7 haloperidol 56 18.7 174 25.4 zuclopenthixol 3 1.0 7 1.0 perphenazine 4 1.3 1 0.1 chlorpromazine 2 0.7 1 0.1 more than one typical 3 1.0 18 2.6 subtotal typical 147 49.2 368 53.8 1 Includes 38 users who died in hospital. 2 Percentages may not sum up to 100% because some subjects were prescribed more than one agent, in particular 38 subjects were prescribed both typical and atypical agents. 3 Percentages may not sum up to 100% because some subjects were prescribed more than one agent, in particular 88 subjects were prescribed both typical and atypical agents.

Antipsychotics mostly atypical, consistently with prior research [Bohlken J et al, 2015; Barry H et al, 2016; Walsh KA et al, 2016; Schmed N et al, 2016]

Linkage with outpatient prescription dispensing database - at the subject-level through individual unique identifier - data on prescription redeemed are registered continuously from 2000 - linkage almost complete (97.6%), not feasible for 46 (2.4%) patients with confirmed dementia

Not confirmed 451 records 23 repeated hospitalizations 423 patients 396 discharged alive

Number and distribution of patients with not confirmed diagnosis of dementia by selected covariates. N % age (years) <65 22 5.2 65-74 61 14.4 75-84 137 32.4 85+ 203 48.0 sex women 255 60.3 men 168 39.7 type of dementia (ICD-9-CM code) presenile dementia (2901) 33 7.8 senile dementia (2900, 2902, 2903) 167 39.5 vascular dementia (2904) 197 46.6 Alzheimer disease (3310) 2 0.5 other 1 24 5.7 psychiatric comorbidity depression 49 11.6 psychosis 6 1.4 other 56 13.2 discharging division neurology 60 14.2 surgery 25 5.9 medicine 335 79.2 1 Includes: alcohol persistent dementia (291.2), drug persistent dementia (292.82), dementia in other diseases/ unspecified (294.1, 294.2, 294.8), frontotemporal dementia (331.1, 331.19), Lewy body dementia (331.82), Jakob-Creutzfeldt disease (046.1), general paresis (094.1), degenerative dementia (290.9), Pick s disease (331.11).

Psychotropic medication prescribed at discharge in patients with not confirmed diagnosis of dementia discharged alive (N= 396). N % antipsychotics 86 21.7 antidepressants 103 26.0 anti-dementia drugs 19 4.8 anxiolytics 38 9.6 hypnotics and sedatives 23 5.8